Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (91-100 of 190) with videos related to

Pageof 19
Sort By:
Rheumatology and Therapy|February 9, 2018
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc AnalysisRoy Fleischmann, Jürgen Wollenhaupt, Stanley Cohen, et al.
Rheumatology and Therapy|March 30, 2017
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis PatientsRoy Fleischmann, Ronald F van Vollenhoven, Jiri Vencovský, et al.
The Journal of Rheumatology|September 16, 2021
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYONDDésirée van der Heijde, Cynthia E Kartman, Li Xie, et al.
Annals of the Rheumatic Diseases|August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsChristina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Rheumatology (Oxford, England)|February 16, 2021
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPAREVibeke Strand, Namita Tundia, Martin Bergman, et al.
RMD Open|January 27, 2017
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritisRoy Fleischmann, Vanita Tongbram, Ronald van Vollenhoven, et al.
RMD Open|July 26, 2024
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND studyRoy Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, et al.
Rheumatology (Oxford, England)|March 2, 2016
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisVibeke Strand, Ronald F van Vollenhoven, Eun Bong Lee, et al.
RMD Open|June 3, 2025
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular diseaseGerd R Burmester, Eduardo Mysler, Peter Taylor, et al.
Nature Reviews. Rheumatology|January 12, 2024
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinicianZoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, et al.
Pageof 19

Showing results (91-100 of 190) with videos related to

Sort By:
Pageof 19
Rheumatology and Therapy|February 9, 2018
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc AnalysisRoy Fleischmann, Jürgen Wollenhaupt, Stanley Cohen, et al.
Rheumatology and Therapy|March 30, 2017
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis PatientsRoy Fleischmann, Ronald F van Vollenhoven, Jiri Vencovský, et al.
The Journal of Rheumatology|September 16, 2021
Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYONDDésirée van der Heijde, Cynthia E Kartman, Li Xie, et al.
Annals of the Rheumatic Diseases|August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsChristina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Rheumatology (Oxford, England)|February 16, 2021
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPAREVibeke Strand, Namita Tundia, Martin Bergman, et al.
RMD Open|January 27, 2017
Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritisRoy Fleischmann, Vanita Tongbram, Ronald van Vollenhoven, et al.
RMD Open|July 26, 2024
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND studyRoy Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, et al.
Rheumatology (Oxford, England)|March 2, 2016
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisVibeke Strand, Ronald F van Vollenhoven, Eun Bong Lee, et al.
RMD Open|June 3, 2025
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular diseaseGerd R Burmester, Eduardo Mysler, Peter Taylor, et al.
Nature Reviews. Rheumatology|January 12, 2024
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinicianZoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, et al.
Pageof 19